The North America Meningococcal Vaccine Market would witness market growth of 7.8% CAGR during the forecast period (2020-2026). Meningococcal meningitis is one of the rarest bacterial infections of the brain but it is potentially devastating in nature. Despite the advancement in the healthcare sector, still more R&D is required to be done as this disease can kill the host in a very short span. One out of 10 meningococcal meningitis patients expire from the disease, and about 15% of the survivors may suffer from some deadly complications, such as brain damage, amputation, or/and deafness.
The first attempt for the development of vaccines against meningitis was taken in the early 1900s and it had variable degrees of success. For the first time in the 1930s, a safe, stable, and effective vaccines were developed against pneumococcal meningitis, and following this in the 1960s, vaccines against meningococcal meningitis produced. Since then, researchers are focused on creating more effective and efficient vaccines against the numerous bacterial that causes meningitis.
Still, there is no single vaccine which is capable of fighting all forms of meningitis, that is why over past few years, research, and development for potential vaccines has grown considerably. There is notable decline in the occurrence of bacterial meningitis, 90% of the reduction in the disease is due to the increasing use of vaccination.
Meningococcal vaccines are perceiving a significant demand in line with a prominent increase in routine immunization. Increasing use of meningococcal vaccines for immunizing special risk groups, such as travellers, or military personnel is fuelling gains in the market.
Based on Brand, the market is segmented into Bexsero, Trumenba, Nimenrix, Menactra, Menveo and Other Brands. Based on Type, the market is segmented into Bivalent, Quadrivalent and Other Types. Based on Age Group, the market is segmented into Infants (0 to 2 years) and Children (2 years & above). Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: Meningococcal Vaccine Market in North America is expected to register a CAGR of 7.8% during the forecast period (2020-2026)
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC (GSK), Pfizer, Inc., Sanofi S.A., Walvax Biotechnology Co., Ltd., Bio-Manguinhos (Oswaldo Cruz Foundation), Bio-Med Pvt. Ltd., Chongqing Zhifei Biological Products Co., Ltd., Hualan Biological Engineering, Inc., Incepta Pharmaceuticals Ltd. and Serum Institute of India Pvt. Ltd. (Poonawalla Investments & Industries Pvt. Ltd.)
By Brand
By Type
By Age Group
By Country
Companies Profiled
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
